Proteomics

Dataset Information

0

Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma

ABSTRACT: HLA class I ligandome dataset obtained from hepatocellular carcinoma (HCC) as well as corresponding adjacent benign liver tissue (n=16) characterizing respective HLA immunoprecipitates. Additionally, from a subset of the mentioned HCC/ adjacent benign liver samples datasets gained from shotgun protein identification, comprising HCC as well as adjacent benign liver tissue (n=7) are provided. Further, for one patient shotgun protein identification was also performed in serum (blood) samples obtained after HCC recurrence.

INSTRUMENT(S): Orbitrap Fusion Lumos, LTQ Orbitrap XL, LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Liver, Epithelial Cell

DISEASE(S): Hepatocellular Carcinoma

SUBMITTER: Leon Bichmann  

LAB HEAD: Hans-Georg Rammensee

PROVIDER: PXD013057 | Pride | 2019-05-06

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
131025_NT_HCC23_Benign_W_20_1_50cm195min5s_msms2.RAW Raw
131025_NT_HCC23_Benign_W_20_1_50cm195min5s_msms2.mzTab Mztab
131025_NT_HCC23_Tumor_LysatReRun_W_20_1_50cm195min5s_msms10.RAW Raw
131025_NT_HCC23_Tumor_W_20_1_50cm195min5s_msms1.RAW Raw
131025_NT_HCC23_Tumor_W_20_1_50cm195min5s_msms1.mzTab Mztab
Items per page:
1 - 5 of 245
altmetric image

Publications

<h4>Background</h4>Although mutated HLA ligands are considered ideal cancer-specific immunotherapy targets, evidence for their presentation is lacking in hepatocellular carcinomas (HCCs). Employing a unique multi-omics approach comprising a neoepitope identification pipeline, we assessed exome-derived mutations naturally presented as HLA class I ligands in HCCs.<h4>Methods</h4>In-depth multi-omics analyses included whole exome and transcriptome sequencing to define individual patient-specific se  ...[more]

Similar Datasets

Proteomics Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics
2023-07-05 | PXD041804 | Pride
Proteomics The HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues
2021-04-16 | PXD020186 | Pride
Proteomics The HLA-Ligand-Atlas. A resource of natural HLA ligands presented on benign tissues
2021-04-16 | PXD019643 | Pride
Proteomics DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts
2023-08-18 | PXD035750 | Pride
Proteomics ADAMTSL5 is an epigenetically activated oncogene conferring tumorigenic properties in hepatocellular carcinoma
2020-11-17 | PXD016634 | Pride
Proteomics The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy
2022-07-19 | PXD035324 | Pride
Transcriptomics Applied Biosystems Human TaqMan Low Density Array (TLDA) in HCC tumor and adjacent non-tumor tissues
2014-02-08 | E-GEOD-54751 | biostudies-arrayexpress
Proteomics Immunopeptidome of HeLa-CIITA cells silenced for TAX1BP1(T6BP) expression
2022-09-22 | PXD024417 | Pride
Proteomics,Multiomics Identification of changes in the LNZ308 HLA immunopeptidome after virotherapy, irradiation and chemotherapy
2018-02-19 | PXD008984 | Pride
Proteomics Mapping the soluble human leukocyte antigen peptidome of pleural effusions reveals lung and tumor-associated antigens
2022-05-25 | PXD027766 | Pride